Overview
GILD market data
Price History
GILD price chart · 1M
- O
- 150.05
- H
- 150.99
- L
- 148.05
- C
- 150.88
- Vol
- 303,742.00
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & Performance
- Open
- $150.05
- Previous Close
- $149.63
- Day High
- $150.99
- Day Low
- $148.05
- 52 Week High
- $153.99
- 52 Week Low
- $119.93
- 7 Day Return
- +0.59%
- 30 Day Return
- +2.43%
- 90 Day Return
- +20.13%
- 1 Year Return
- +13.59%
- Daily Notional Volume
- $45.8M Latest daily bar volume multiplied by its closing price.
Valuation & Profitability
- P/E (TTM)
- 21.74 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $6.78 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.40 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- 4.0% Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -10.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $108.46 – $157.29 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $185B · P/B 6.71 · P/S 6.07.
Company News
10 captured
CAR T-Cell Therapy for Non-Hodgkin’s Lymphoma Market Set for Expansion Through 2036, Fueled by Treatment Innovation and Rising Patient DemandGlobenewswire Inc ·
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market Set for Strong Growth Through 2036, Driven by Next-Generation Innovation and Expanding Patient AccessGlobenewswire Inc ·
Gilead Exec Says HIV Market Growth Should Normalize To 2%-3% Within Next Couple Of QuartersBenzinga ·
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent CliffZacks Investment Research ·